Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Feb 9.
doi: 10.1111/hepr.70138. Online ahead of print.

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

Yasuto Takeuchi  1 , Masahiko Sue  1 , Nozomi Miyake  1 , Takuya Adachi  1 , Hideki Onishi  1 , Miwa Kawanaka  1 , Akinobu Takaki  1 , Kazuhiro Nouso  2 , Kazuya Kariyama  2 , Shinichiro Nakamura  3 , Emi Tanaka  3 , Toshifumi Tada  4 , Tetsuya Yasunaka  5 , Kenji Kuwaki  6 , Junichi Toshimori  7 , Shota Iwado  8 , Akio Moriya  9 , Hiroaki Hagihara  10 , Hiroyuki Takabatake  11 , Masahiro Sakata  12 , Motoyuki Otsuka  1
Affiliations

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

Yasuto Takeuchi et al. Hepatol Res. .

Abstract

Background: Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). However, validated criteria for predicting eligibility for conversion remain unclear. We investigated the utility of the recently proposed borderline resectable (BR) classification combined with the barcelona clinic liver cancer (BCLC) staging system to identify patients most likely to benefit from conversion following atezolizumab plus bevacizumab (ATZ/BEV) therapy.

Methods: In this multicenter retrospective study, 532 patients with unresectable HCC treated with ATZ/BEV were categorized using the BR classification and stratified according to the BCLC stage. We evaluated objective response rate (ORR), conversion rate, and overall survival (OS) and carried out multivariate logistic regression analysis to identify predictors of conversion.

Results: Conversion therapy was performed in 5.9% of patients. Among those with BCLC-C HCC, the conversion rate was significantly higher in BR1 HCC than in BR2 HCC (15.2% vs. 2.0% and p < 0.01), and BR1 status was independently associated with conversion (odds ratio 7.0). Patients with BCLC-C/BR1 staging showed the highest ORR (45.0%) and favorable OS after conversion (p = 0.015). In contrast, the BR classification had limited predictive value in patients with BCLC-B HCC. Notably, downstaging from BR1 to resectable status was more common than from BR2, suggesting higher conversion feasibility.

Conclusions: Integrating BR classification with BCLC staging identified BCLC-C/BR1 patients as optimal candidates for conversion therapy after ATZ/BEV treatment. These findings support incorporating anatomical and oncological criteria into systemic strategies to enable curative interventions in advanced HCC.

Keywords: atezolizumab plus bevacizumab; barcelona clinic liver cancer stage; borderline resectable classification; conversion therapy; hepatocellular carcinoma.

PubMed Disclaimer

References

    1. M. G. Rose, E. B. Kennedy, G. K. Abou‐Alfa, et al., “Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights,” JCO Oncology Practice 20, no. 8 (August 2024): 1035–1039, https://doi.org/10.1200/OP.24.00189.
    1. A. Vogel, A. Cervantes, I. Chau, et al., “Hepatocellular Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and follow‐up,” supplement, Annals of Oncology 29, no. S4 (October 2018): iv238–iv255, https://doi.org/10.1093/annonc/mdy308.
    1. A. L. Cheng, S. Qin, M. Ikeda, et al., “Updated Efficacy and Safety Data From IMbrave150: Atezolizumab Plus Bevacizumab s. Sorafenib for Unresectable Hepatocellular Carcinoma,” Journal of Hepatology 76, no. 4 (April 2022): 862–873, https://doi.org/10.1016/j.jhep.2021.11.030.
    1. M. Kudo, T. Aoki, K. Ueshima, et al., “Achievement of Complete Response and Drug‐Free Status by Atezolizumab plus Bevacizumab Combined With or Without Curative Conversion in Patients With Transarterial Chemoembolization‐Unsuitable, Intermediate‐Stage Hepatocellular Carcinoma: A Multicenter Proof‐of‐Concept Study,” Liver Cancer 12, no. 4 (February 2023): 321–338, https://doi.org/10.1159/000529574.
    1. T. Kikuchi, Y. Takeuchi, K. Nouso, et al., “Predictive Factors for Transition to Conversion Therapy in Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab,” Liver International 44, no. 6 (June 2024): 1456–1463, https://doi.org/10.1111/liv.15907.

LinkOut - more resources